Company Overview and News

1
MCHP / Microchip Technology Inc. SD

2018-05-23 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION

 
MCHP / Microchip Technology Inc. FORM 8-K (Current Report)

2018-05-21 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

 
MCHP / Microchip Technology Inc. FORM 8-K (Current Report)

2018-05-21 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

 
Microchip Technology Announces Intention to Offer Senior Secured Notes of Multiple Tranches

2018-05-21 globenewswire
CHANDLER, Ariz., May 21, 2018 (GLOBE NEWSWIRE) -- Microchip Technology Incorporated (NASDAQ:MCHP) (“Microchip,” “we” or “our”) announced today that it has commenced an unregistered offering of senior secured notes of multiple tranches (the “Notes”). Microchip intends to use a combination of the net proceeds from the offering of the Notes, cash on hand, borrowings under its revolving credit facility and borrowings under a new term loan facility to fund the cash consideration and other amounts payable in respect of its previously announced acquisition of Microsemi Corporation (the “Microsemi Merger”).

 
Semiconductor Canaries: Chirp, Warble... Soon A Croak And Silence?

2018-05-20 seekingalpha
In January of 2013 we used the Semi Equipment segment to project a firm broad Semi cycle and later, economic cycle.

3
MCHP / Microchip Technology Inc. 10-K (Annual Report)

2018-05-18 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION

 
MCHP / Microchip Technology Inc. 8-K (Current Report)

2018-05-18 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

1
Beijing Approves Microchip Deal, Boding Well For Qualcomm-NXP

2018-05-17 seekingalpha
China’s approval of a small US chip merger shows Beijing is actively reviewing such deals again after a brief pause to show its displeasure over US trade tensions.

 
Deals of the day-Mergers and acquisitions

2018-05-16 reuters
May 16 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1030 GMT on Wednesday:

 
MCHP / Microchip Technology Inc. DFAN14A

2018-05-15 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION

 
MCHP / Microchip Technology Inc. DFAN14A

2018-05-15 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION

 
Microchip gets China antitrust approval to buy Microsemi

2018-05-15 reuters
(Reuters) - Microchip Technology Inc (MCHP.O) said on Tuesday it has received antitrust approval from China to buy rival Microsemi Corp (MSCC.O), clearing a major hurdle to the $8.35 billion deal.

 
Ceva, Inc. Or Microchip Technology Incorporated: Which Is The Better Way To Play Chipmakers?

2018-05-10 seekingalpha
Here is what price range forecasts shake out of the hedging bushes from the market-making community due to the big-money-fund portfolio managers' block-trade order activity.

1
MCHP / Microchip Technology Inc. DFAN14A

2018-05-09 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION

1
MCHP / Microchip Technology Inc. DFAN14A

2018-05-09 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

CUSIP: 595017104